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Enrichment of rare variants in population isolates:
single AICDA mutation responsible for hyper-IgM
syndrome type 2 in Finland
Luca Trotta1, Timo Hautala2, Sari Hämäläinen3, Jaana Syrjänen4, Hanna Viskari4,5, Henrikki Almusa1,
Maija Lepisto1, Meri Kaustio1, Kimmo Porkka6, Aarno Palotie1,7, Mikko Seppänen*,8,9,10 and Janna Saarela*,1,10
Antibody class-switch recombination and somatic hypermutation critically depend on the function of activation-induced cytidine
deaminase (AID). Rare variants in its gene AICDA have been reported to cause autosomal recessive AID deﬁciency (autosomal
recessive hyper-IgM syndrome type 2 (HIGM2)). Exome sequencing of a multicase Finnish family with an HIGM2 phenotype
identiﬁed a rare, homozygous, variant (c.416T4C, p.(Met139Thr)) in the AICDA gene, found to be signiﬁcantly enriched in the
Finnish population compared with other populations of European origin (38.56-fold, Po0.001). The population history of
Finland, characterized by a restricted number of founders, isolation and several population bottlenecks, has caused enrichment
of certain rare disease-causing variants and losses of others, as part of a phenomenon called the Finnish Disease Heritage.
Accordingly, rare founder mutations cause the majority of observed Finnish cases in these mostly autosomal recessive disorders
that consequently are more frequent in Finland than elsewhere. Screening of all currently known Finnish patients with an
HIGM2 phenotype showed them to be homozygous for p.(Met139Thr). All the Finnish p.(Met139Thr) carriers with available data
on their geographic descent originated from the eastern and northeastern parts of Finland. They were observed to share more of
their genome identity by descent (IBD) than Finns in general (Po0.001), and they all carried a 207.5-kb ancestral haplotype
containing the variant. In conclusion, the identiﬁed p.(Met139Thr) variant is signiﬁcantly enriched in Finns and explains all thus
far found AID deﬁciencies in Finland.
European Journal of Human Genetics (2016) 24, 1473–1478; doi:10.1038/ejhg.2016.37; published online 4 May 2016
INTRODUCTION
Primary immunodeﬁciency disorders (PIDDs) encompass a wide
range of genetically determined inborn errors of immunity. Presently,
45000 variants affecting the function have been reported in over 250
genes as causative of 265 PIDDs, and novel defects continue to be
discovered.1
Hyper-IgM syndromes (HIGMs) include a genetically heteroge-
neous group of PIDDs deﬁned by early-onset recurrent infections and
autoimmunity, absence or very low levels of IgG, IgA and IgE, but
elevated or normal serum IgM levels.2 This phenotype typically results
from inherited defects in proteins involved in class-switch recombina-
tion (CSR) and somatic hypermutation (SHM). Classical HIGM-
causing genes include CD40LG, AICDA, CD40 and UNG.3 CSR, SHM
and central B-cell tolerance critically depend on normal activation-
induced cytidine deaminase (AID) function.4–6 AID also participates
in removal of epigenetic memory by active demethylation.7 The
immunologic HIGM phenotypes of AID and uracil DNA glycosylase
(UNG) deﬁciencies closely resemble each other and are relatively easy
to screen. In these, no CD19+CD27+IgD-IgM- switched memory
B (smB) cells can be found in blood, whereas marginal zone CD19+
CD27+IgD+IgM+ B (MZB) cells are normal or high. AID deﬁciency is
estimated to affect o2/107 individuals.8
The population history of Finland is characterized by a restricted
number of founders, isolation, several population bottlenecks
and recent expansion of the population. This has led to the
enrichment of some deleterious variants and loss of others,
creating a phenomenon called the Finnish Disease Heritage
(FDH). By deﬁnition, FDH disorders are more frequent in Finland
than elsewhere, and a majority of the Finnish patients share the
same founder mutation.9
Here, we have identiﬁed the Finnish founder allele causing HIGM2
and assessed its prevalence in Finns compared with other populations.
MATERIALS AND METHODS
This study was conducted in accordance to the principles of the Helsinki
Declaration and was approved by the Coordinating Ethics Committee of
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Helsinki University Hospital. Written informed consent was obtained from all
subjects.
Patients
The index case of the family I (I-I) was immunologically characterized in
Helsinki University Hospital. She has undetectable level of smB cells and a typical
clinical picture of HIGM2 (Table 1). Next, patient cohorts of the pediatric and
adult immunodeﬁciency units of all ﬁve Finnish university hospitals were
screened for patients with a phenotype compatible with either AID or UNG
deﬁciency. All subsequent patients (families II–IV) with (1) low or absent IgA,
IgG and IgE levels but normal or high IgM levels according to the laboratory
reference values, together with (2) missing smB cells but normal or high levels of
MZB in B-cell phenotyping (for methods see Haapaniemi et al10) were included
in the study. Study subjects underwent clinical and immunological evaluations at
Helsinki, Kuopio, Oulu and Tampere University Hospitals. All available patient
records since June 1959 were reviewed and patients interviewed. Altogether, four
families were identiﬁed (Table 1 and Figure 1). Patient histories are described in
detail in the Supplementary Information.
Molecular genetics
Genomic DNA of the studied individuals was isolated using standard salt
precipitation protocols.
Exome sequencing was performed in the two index patients of family I and
in two of their healthy relatives to investigate the genetic basis of their familial
disease presentation. A NexteraRapid Capture Exome kit (Illumina, San Diego,
CA, USA) was used for library preparation and exome enrichment and
sequencing was performed on a HiSeq 1500 platform (Illumina). The data
were analyzed using a version 2.7 of the in-house developed analysis pipeline
for quality control and variant identiﬁcation (VCP).11 Detailed sequencing
statistics and procedures for read alignment and variant calling are provided in
the Supplementary Information. Additional patients were screened for AIDCA
allelic variants by Sanger sequencing. The analysis of the AICDA gene
(GRCh37.p13:12:8754762-8765463) and the primer design were performed
using the following genomic and transcript sequences: RefSeq NG_011588.1
and NM_020661.2. The identiﬁed variants and other patient data were
deposited in the LOVD database (http://databases.lovd.nl/shared/genes/AICDA)
(variant ID: AICDA_000004; individual IDs: 00058568, 00058569, 00058570,
00058572, 00058573, 00058574 and 00058575).
DNA variants were veriﬁed by restriction endonuclease digestion. See
Supplementary Information for the sequence of primers and further description
of the procedures.
Population analysis
We performed a population-based analysis of the identiﬁed sequence variant
frequency by using data of 60 786 individuals from Exome Aggregation
Consortium including 34 699 individuals of European origin, of whom 3013
were Finnish.
The geographic distribution in Finland of the p.(Met139Thr) alleles (RefSeq
NM_020661.2; c.416T4C; rs200858797) was illustrated based on the informa-
tion obtained from the study subjects and from the carriers included in the SISu
project (http://sisu.ﬁmm.ﬁ/)12 for which such data were available and in three
Finnish sample collections (the Finnish Twin Cohort study, the National
Finrisk Study and the Migraine Family Study; Supplementary Information,
Supplementary Table 1 and Figure 2).
The analysis of pairwise segmental sharing was conducted on a set of 6755
Finns included in epidemiological and clinical Finnish sample collections,
of whom 20 were p.(Met139Thr) carriers, using 113 common markers gen-
otyped using HumanCoreExome-24 BeadChips (Illumina; 1000 Genomes;
Figure 1 AICDA variants in four families with HIGM2. Solid symbols indicate affected patients and open symbols unaffected family members. Triangles
represent stillborn individuals. Slashes indicate deceased persons (reported cause of death is sepsis (65 y.o.) for I-I, and meningitis (2 y.o.) for I–III). The
original familial probands (index cases) are pointed by arrows. The AICDA p.(Met139Thr) variant is indicated by M, wild-type alleles by N. aIndividuals
evaluated by whole-exome sequencing. bTargeted analysis of the p.(Met139Thr) variant by Sanger sequencing.
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www.1000genomes.org; accessed 18 April 2014). A cryptic relatedness analysis
was performed by using the identity by descent (IBD) estimation on the above-
mentioned set of unaffected individuals (Supplementary Information).
In parallel, a segregation analysis of polymorphisms in a 2-Mb region
encompassing the p.(Met139Thr) was executed in the 32 carriers included in
the above mentioned clinical and epidemiological sample collections in
addition to the SISu data set (Supplementary Table 2) by utilizing PLINK
(v. 1.07, http://pngu.mgh.harvard.edu/purcell/plink/).13 Next, according to the
observed haplotype blocks, a total of 80 markers located in a 1.1-Mb region
surrounding the p.(Met139Thr) were screened for a putative shared allele,
carried on in the comprehensive group of 32 carriers (Supplementary Table 3).
Statistical analysis
Pearson’s χ2 test (108 simulations) was used to evaluate the different
p.(Met139Thr) allelic distributions among Finns and the more heterogeneous
European populations (Supplementary Table 4), and the load of hidden
relatedness among the carriers and the general population was weighed using
Welch’s two-sample t-test (108 simulations).
RESULTS
Genetic analysis
We ﬁrst studied a family with four affected individuals originating
from Eastern Finland (Figure 1). The index of the family had
previously been tested in a reference laboratory to have wild-type
AICDA and UNG. However, exome sequencing revealed a known
biallelic AIDCA variant in the living affected members
(p.(Met139Thr)) that has previously been shown to cause HIGM2.14
The two healthy relatives carried one copy of the variant. Targeted
Sanger sequencing of an archived sample from the index veriﬁed
the presence of the same biallelic sequence change (I-I, Figure 1).
Thereafter, all remaining Finnish patients with a compatible pheno-
type (n= 4) were screened and found homozygotes for the
p.(Met139Thr) variant (Figure 1 and Table 1).
Population analysis
Overall, we found the HIGM2 causing p.(Met139Thr) alteration to have
a frequency of 0.012% in a total of 57 391 exomes provided by the
Exome Aggregation Consortium (ExAC). More detailed analysis of the
data revealed an allelic frequency of 0.0047% in 31 686 individuals of
European ancestry (non-Finns) and the absence of the variant in non-
European populations (22 692 individuals). Compared with other
populations of European origin, a statistically signiﬁcant 38.56-fold
allelic frequency was observed in Finns with 11 uniallelic carriers in
3013 exomes (0.18%, Po0.001; Supplementary Table 4), resulting in
the calculated theoretical frequency of AID deﬁciency of 0.81/106 in
those of Finnish ancestry. Other AICDA variants showed no substantial
differences in frequencies between the populations (data not shown).
Because of the enrichment of the p.(Met139Thr) variant in Finland,
we studied its geographical distribution based on the information on
birthplace retrieved from the studied subjects, and from those 27 out
of 31 carriers within the SiSu cohort and other Finnish sample
collections with such data available. Interestingly, all of the AID
deﬁciency patients and 24 of the 27 carriers originated from the late
settlement regions of Eastern and Northeastern Finland, suggesting
shared origin for the p.(Met139Thr) alleles in all these individuals
(Figure 2). The remaining three carriers were born in Helsinki area
that has experienced substantial immigration from the rest of the
country during recent centuries. Thus, we searched for possible shared
haplotype in the region surrounding AICDA by utilizing the exome
data for 3325 individuals of the SiSu cohort, including 11
p.(Met139Thr) carriers. We ﬁrst retrieved the haplotype structure of
the 2 Mb genomic region encompassing the p.(Met139Thr) and
observed clear haplotype blocks 90 kb upstream and 51 kb down-
stream of the variant (Supplementary Table 5). Further examination of
the genomic region ﬂanking AICDA using the UCSC Genome
Browser15 revealed the presence of a 10-kb recombination hot spot
encompassing the gene that likely weakens the possibility of tracking a
conserved ancestral allele. Nonetheless, by combining the genetic data
of all the 31 carriers of the two different population-based data sets
(exome data of the SiSu cohort and genotyping data of the Finnish
epidemiological and clinical cohorts) and the two exome sequenced
familial carriers, and by monitoring the alleles seen in each haplotype
block, we identiﬁed a 207.5-kb core haplotype including the
p.(Met139Thr) variant shared by all the carriers (Figure 3). The
minimal shared region was restricted by recombination in ﬁve
individuals, whereas the core haplotype extended signiﬁcantly further
in the others (Figure 3). Further comparison of the pairwise genome-
wide IBD showed higher values in the group of p.(Met139Thr) carriers
(average piHat= 0.007± 0.0027) than in the general population
(piHat= 0.003± 0.005), displaying signiﬁcant increased relatedness
within the carriers (P= 1.59E− 12).
DISCUSSION
In the current study, we identiﬁed a Finnish founder mutation for
AID deﬁciency. The rare recessive p.(Met139Thr) allelic variant in
the AICDA gene causes the disease in all known Finnish patients.
The variant, previously conﬁrmed to affect the AID function in a
Figure 2 Distribution of the AICDA p.(Met139Thr) carriers in Finland. Blue
triangles point to the geographical origin of the Finnish carriers (n=27) of
the p.(Met139Thr) variant included in SISu and in epidemiological and
clinical Finnish sample collections (the Finnish Twin Cohort study, the
National Finrisk Study and the Migraine Family Study) (Supplementary
Table 1). Yellow symbols indicate the birthplaces of carriers’ parents, if
discordant. The birthplaces of the patients identiﬁed in this study are
indicated by a purple spot, listing the number of the family (from I to IV).
For families III and IV, the mother corresponds to ‘a’ and the father to ‘b’.
The black dots mark the main municipal areas.
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single HIGM2 patient of unknown origin,14 exhibits a signiﬁcant
(38.56-fold) enrichment in Finns compared with the data from other
European populations.
There are at least 117 previously published cases of AID deﬁciency
and, currently, at least 43 autosomal recessive or dominant negative
causative AICDA variants have been reported.16–19 The observed
p.(Met139Thr) change affects an evolutionarily conserved amino acid
residue in the APOBEC-like domain, and in silico analyses are
consistent with a deleterious effect, resulting in severely impaired
CSR.15 Interestingly, a different causative missense substitution affect-
ing the same amino acid has been found in three Turkish patients
with HIGM2 (RefSeq NM_020661.2; c.415A4G, p.(Met139Val);
rs104894321).20,21 This disrupts the AID activity in vitro.22
Given the known frequency of uniallelic p.(Met139Thr) in 3013
Finns, the predicted prevalence for homozygous individuals was
~ 0.81/106. However, the presently known prevalence of AID deﬁ-
ciency in Finland is 1.5/106, greatly exceeding the estimate in literature,
although this was partly based on the incidence in French-Canadians,
the other known population with an AICDA founder mutation.8
Currently, there are relatively few Northern and Northeastern Finns
in the SISu cohort, potentially explaining the observed difference
between theoretical and known prevalence. To evaluate the contribu-
tion of other variants causing HIGMs in the Finnish population, we
performed a similar population-based comparison of allele frequencies
for all the variants in genes affecting CSR (AICDA, UNG, CD40 and
CD40LG). None of the other allelic variants were signiﬁcantly enriched
in the Finnish cohort compared with other European populations.
Finland’s population history has led to an enrichment of some
disease-causing variants and losses of others. In each FDH disorder, a
causative Finmajor founder mutation accounts for most, if not all,
affected individuals and is more frequent in Finland than elsewhere.23
FDH thus far has included three PIDDs: cartilage-hair hypoplasia
(CHH), autoimmune polyendocrinopathy (APECED) and Cohen
syndrome, with a prevalence of 50/106, 36/106 and 10/106,
respectively.9,24–28 The currently available exome data further con-
ﬁrmed the Finmajor mutations causing APECED (rs121434254, 6.25-
fold) and Cohen syndrome (rs180177327, 47.11-fold) to be signiﬁ-
cantly enriched in Finns compared with other populations. No reliable
data are available for the CHH-associated variants.
As almost all p.(Met139Thr) carriers originated from the late
settlement areas of Eastern and Northeastern Finland, the geographic
distribution of the variant ﬁts well with the known inhabitation patterns
of the country and suggest a single origin.29,30 Consequently, we made an
effort to validate this hypothesis by analyzing the genomic region
encompassing the AICDA gene in the individuals of the SiSu cohort.
We identiﬁed linkage disequilibrium blocks upstream and downstream
the p.(Met139Thr), suggesting the actual architecture of the region as
reﬂecting the remnants of a wider previous haplotype that has potentially
included the variant. The small number of the carriers and, mostly, the
presence of a recombination hot spot of 10 kb surrounding the AICDA
gene31 could have limited our ability to identify the ancestral allele. In
order to overcome these limitations, we further studied the haplotype
structure of the surrounding areas in all the p.(Met139Thr) carriers
included in the SiSu project and three epidemiological and clinical
Finnish sample collections. A segregation analysis revealed a shared
haplotype of 207.57 kb inclusive of the variant, with no apparent
recombination events in the 31 carriers. This was surrounded by a
partially conserved genomic region of 901 kb where a limited amount of
recombination events had taken place. The outlined genetic structure
comprises the likely ancestral founder allele. Our hypothesis of a single
mutation event and shared ancestry was also further strengthened by
the ﬁnding that all p.(Met139Thr) carriers shared more of their
genome than the general population (2.25-fold increased IBD).
AID deﬁciency is clinically characterized by severe antibody deﬁ-
ciency, lymphatic nongranulomatous hyperplasia with hyperplastic
germinal centers and inﬂammatory complications like hematologic
Figure 3 Haplotype structure of the ﬂanking region of the AICDA gene in the 31 Finnish carriers of p.(Met139Thr) variant. The haplotypes of the carriers
analyzed by genotyping chip (the Finnish Twin Cohort study, the National Finrisk Study and the Migraine Family Study) are shown on horizontal lines on
yellow background in the top part of the panel. The haplotypes of the carriers analyzed by WES (SISu project and study subjects of family I) are presented on
blue background. The red column shows the position of the p.(Met139Thr) variant. Missing genotypes are marked by ‘-’. The yellow/blue squares show the
identiﬁed shared haplotype in each mutation carrier, white ﬁlling indicates noninformative genotypes and black squares label recombination event (ie,
absence of the allele included in the above mentioned haplotype). The minimum regions shared by all mutation carriers in each data set are indicated by
darker color. aThe markers used in the analysis are indicated with numbers in the top row (marker names listed in Supplementary Table 3). bThe columns
framed by black lines highlight the markers shared by both data sets, and the alleles seen in the shared haplotype are shown above the column.
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autoimmunity, chronic hepatitis, diarrhea and aseptic arthritis.16,17 Our
patients display a uniform matching phenotype. The patients of family I
have a longer follow-up than most patients in the current literature,
lending insight into the long-term consequences of the disease. To the
best of our knowledge, the patients have developed several previously
unreported systemic, renal and gastrointestinal autoimmune complica-
tions (Table 1 and Supplementary Information). However, aggressively
substituted younger patients in families II–IV seem to have few
autoimmune problems. Unlike in common variable immunodeﬁciency,
granulomatous lymphadenitis is not a previously described feature of
AID deﬁciency. A pronounced and difﬁcult to treat granulomatous
lymphadenopathy was noted in family I and conﬁrmed by biopsies.
Unfortunately, no archived tissue samples were available. As this
occurred during a familial tuberculous mini-epidemic, it suggests that
infectious causes of granulomas should always be excluded in AID
deﬁciency. Opportunistic lethal infections in I-I were likely caused by
secondary immunosuppression and are also not a feature of AID
deﬁciency. Whether AID deﬁciency is able to cause spontaneously
terminated pregnancies should be further studied (cf. Supplementary
Information).
In summary, we identiﬁed a single variant affecting the function of
the protein accounting for all diagnosed AID deﬁciencies in Finns. In
all likelihood, p.(Met139Thr) is a Finmajor founder mutation and AID
deﬁciency belongs to the FDH. This phenomenon closely resembles
the known p.Arg112Cys founder allele in French Canadians, but
3p.(Met139Thr) is even more prevalent in Finns.8 Taken together,
these ﬁndings underline the correlation between the genetic structure
of the population and the distribution of genetic disorders, and
emphasize the beneﬁts of researching population isolates with
systematic health records available.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We are very grateful to Dr Jaana Hyytiäinen for providing additional data on
our patients. We thank the Exome Aggregation Consortium, and a full list
of contributing groups can be found at http://exac.broadinstitute.org/about. Teemu
Kuulasmaa and Markku Laakso are thanked for kindly sharing the genetic data
and geographic origin of p.(Met139Thr) carriers included in the METSIM study
(http://www.nationalbiobanks.ﬁ/index.php/studies2/10-metsim). We thank THL
National FINRISK Study participants and its scientiﬁc team for their contribution
to this study. Jaakko Kaprio is thanked for providing access to the Finnish Twin
Cohort data, with the support of the Academy of Finland (Grants 265240 and
263278). The exome sequencing and primary data analysis was provided by the
Sequencing and Bioinformatics Units of the FIMM Technology Centre.
1 Al-Herz W, Bousﬁha A, Casanova JL et al: Primary immunodeﬁciency diseases: an
update on the classiﬁcation from the international union of immunological societies
expert committee for primary immunodeﬁciency. Front Immunol 2014; 5: 162.
2 Gulino AV, Notarangelo LD: Hyper IgM syndromes. Curr Opin Rheumatol 2003; 15:
422–429.
3 Durandy A, Taubenheim N, Peron S, Fischer A: Pathophysiology of B-cell intrinsic immuno-
globulin class switch recombination deﬁciencies. Adv Immunol. 2007; 94: 275–306.
4 Kuraoka M, Holl TM, Liao D et al: Activation-induced cytidine deaminase mediates
central tolerance in B cells. Proc Natl Acad Sci USA 2011; 108: 11560–11565.
5 Meyers G, Ng YS, Bannock JM et al: Activation-induced cytidine deaminase (AID) is
required for B-cell tolerance in humans. Proc Natl Acad Sci USA 2011; 108:
11554–11559.
6 Cogne M: Activation-induced deaminase in B lymphocyte maturation and beyond.
Biomed J 2013; 36: 259–268.
7 Kumar R, DiMenna L, Schrode N et al: AID stabilizes stem-cell phenotype by removing
epigenetic memory of pluripotency genes. Nature 2013; 500: 89–92.
8 Minegishi Y, Lavoie A, Cunningham-Rundles C et al: Mutations in activation-induced
cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol 2000; 97:
203–210.
9 Peltonen L, Jalanko A, Varilo T: Molecular genetics of the Finnish disease heritage.
Hum Mol Genet 1999; 8: 1913–1923.
10 Haapaniemi EM, Kaustio M, Rajala HL et al: Autoimmunity, hypogammaglobulinemia,
lymphoproliferation, and mycobacterial disease in patients with activating mutations
in STAT3. Blood 2015; 125: 639–648.
11 Sulonen AM, Ellonen P, Almusa H et al: Comparison of solution-based exome capture
methods for next generation sequencing. Genome Biol. 2011; 12: R94.
12 Lim ET, Wurtz P, Havulinna AS et al: Distribution and medical impact of
loss-of-function variants in the Finnish founder population. PLoS Genet 2014; 10:
e1004494.
13 Purcell S, Neale B, Todd-Brown K et al: PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet 2007; 81:
559–575.
14 Durandy A, Peron S, Taubenheim N, Fischer A: Activation-induced cytidine deaminase:
structure-function relationship as based on the study of mutants. Hum Mutat 2006;
27: 1185–1191.
15 Kent WJ, Sugnet CW, Furey TS et al: The human genome browser at UCSC. Genome
Res 2002; 12: 996–1006.
16 Mahdaviani SA, Hirbod-Mobarakeh A, Wang N et al: Novel mutation of the
activation-induced cytidine deaminase gene in a Tajik family: special review
on hyper-immunoglobulin M syndrome. Expert Rev Clin Immunol 2012; 8:
539–546.
17 Caratao N, Cortesao CS, Reis PH et al: A novel activation-induced cytidine deaminase
(AID) mutation in Brazilian patients with hyper-IgM type 2 syndrome. Clin Immunol
2013; 148: 279–286.
18 Lee WI, Huang JL, Yeh KW et al: Clinical features and genetic analysis of Taiwanese
patients with the hyper IgM syndrome phenotype. Pediatr Infect Dis J 2013; 32:
1010–1016.
19 Cabral-Marques O, Klaver S, Schimke LF et al: First report of the Hyper-IgM syndrome
Registry of the Latin American Society for Immunodeﬁciencies: novel mutations,
unique infections, and outcomes. J Clin Immunol 2014; 34: 146–156.
20 Revy P, Muto T, Levy Y et al: Activation-induced cytidine deaminase (AID) deﬁciency
causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000;
102: 565–575.
21 Quartier P, Bustamante J, Sanal O et al: Clinical, immunologic and genetic analysis of
29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced
Cytidine Deaminase deﬁciency. Clin Immunol 2004; 110: 22–29.
22 Ta VT, Nagaoka H, Catalan N et al: AID mutant analyses indicate requirement for class-
switch-speciﬁc cofactors. Nat Immunol 2003; 4: 843–848.
23 Norio R: The Finnish Disease Heritage III: the individual diseases. Hum Genet 2003;
112: 470–526.
24 Makitie O, Perheentupa J, Kaitila I: Growth in cartilage-hair hypoplasia. Pediatr Res
1992; 31: 176–180.
25 Neufeld M, Maclaren NK, Blizzard RM: Two types of autoimmune Addison's disease
associated with different polyglandular autoimmune (PGA) syndromes. Medicine
(Baltimore) 1981; 60: 355–362.
26 Norio R: Finnish Disease Heritage I: characteristics, causes, background. Hum Genet
2003; 112: 441–456.
27 Ridanpaa M, van Eenennaam H, Pelin K et al: Mutations in the RNA component of
RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 2001;
104: 195–203.
28 Polvi A, Linturi H, Varilo T et al: The Finnish disease heritage database (FinDis)
update-a database for the genes mutated in the Finnish disease heritage brought to the
next-generation sequencing era. Hum Mutat 2013; 34: 1458–1466.
29 Kittles RA, Perola M, Peltonen L et al: Dual origins of Finns revealed by Y chromosome
haplotype variation. Am J Hum Genet 1998; 62: 1171–1179.
30 Palo JU, Ulmanen I, Lukka M, Ellonen P, Sajantila A: Genetic markers and population
history: Finland revisited. Eur J Hum Genet 2009; 17: 1336–1346.
31 Kong A, Gudbjartsson DF, Sainz J et al: A high-resolution recombination map of the
human genome. Nat Genet 2002; 31: 241–247.
This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 Inter-
national License. The images or other third party material in
this article are included in the article’s Creative Commons license,
unless indicated otherwise in the credit line; if the material is not
included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/4.0/
Supplementary Information accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)
Enrichment of a HIGM2-causing mutation in Finland
L Trotta et al
1478
European Journal of Human Genetics
